247 related articles for article (PubMed ID: 34180719)
1. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial.
Adas G; Cukurova Z; Yasar KK; Yilmaz R; Isiksacan N; Kasapoglu P; Yesilbag Z; Koyuncu ID; Karaoz E
Cell Transplant; 2021; 30():9636897211024942. PubMed ID: 34180719
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
3. Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19.
Vassiliou AG; Dimopoulou I; Jahaj E; Keskinidou C; Mastora Z; Orfanos SE; Kotanidou A
In Vivo; 2021; 35(2):1295-1298. PubMed ID: 33622933
[TBL] [Abstract][Full Text] [Related]
4. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
[TBL] [Abstract][Full Text] [Related]
6. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial.
Rebelatto CLK; Senegaglia AC; Franck CL; Daga DR; Shigunov P; Stimamiglio MA; Marsaro DB; Schaidt B; Micosky A; de Azambuja AP; Leitão CA; Petterle RR; Jamur VR; Vaz IM; Mallmann AP; Carraro Junior H; Ditzel E; Brofman PRS; Correa A
Stem Cell Res Ther; 2022 Mar; 13(1):122. PubMed ID: 35313959
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.
Sahu KK; Siddiqui AD; Cerny J
Lab Med; 2021 Jan; 52(1):24-35. PubMed ID: 32729620
[TBL] [Abstract][Full Text] [Related]
8. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
Front Immunol; 2021; 12():745515. PubMed ID: 34858403
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms.
Zhu R; Yan T; Feng Y; Liu Y; Cao H; Peng G; Yang Y; Xu Z; Liu J; Hou W; Wang X; Li Z; Deng L; Wang S; Li J; Han Q; Li H; Shan G; Cao Y; An X; Yan J; Zhang Z; Li H; Qu X; Zhu J; Zhou S; Wang J; Zhang F; Gao J; Jin R; Xu D; Ma YQ; Huang T; Peng S; Zheng Z; Stambler I; Gilson E; Lim LW; Moskalev A; Cano A; Chakrabarti S; Ulfhake B; Su H; Xu H; Xu S; Wei F; Brown-Borg HM; Min KJ; Ellison-Hughes G; Caruso C; Jin K; Zhao RC
Cell Res; 2021 Dec; 31(12):1244-1262. PubMed ID: 34702946
[TBL] [Abstract][Full Text] [Related]
10. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.
Liu Y; Tan W; Chen H; Zhu Y; Wan L; Jiang K; Guo Y; Tang K; Xie C; Yi H; Kuang Y; Luo Y
BMC Infect Dis; 2021 Jan; 21(1):79. PubMed ID: 33461503
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19.
Chaudhary JK; Saini D; Chaudhary PK; Maurya A; Verma GK; Gupta AK; Roshan R; Vats TK; Garg N; Yadav D; Kant N; Meena AK; Mirza-Shariff AA
Cells; 2022 Jul; 11(14):. PubMed ID: 35883618
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of cytokines and lymphocyte subsets associated with the poor prognosis of severe COVID-19.
Li Q; Xu W; Li WX; Huang CL; Chen L
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12536-12544. PubMed ID: 33336774
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the effects of immunotherapy and mesenchymal stem cells transplantation in the treatment of critically ill coronavirus disease 2019 patients].
Yan Y; Jiang X; Ding D; Huang J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):139-144. PubMed ID: 33729129
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey.
O Ercelen N; Pekkoc-Uyanik KC; Alpaydin N; Gulay GR; Simsek M
Stem Cell Rev Rep; 2021 Oct; 17(5):1917-1925. PubMed ID: 34319510
[TBL] [Abstract][Full Text] [Related]
17. Effect of artificial liver blood purification treatment on the survival of critical ill COVID-19 patients.
Dai X; Zhang Y; Yu L; Jiang YA; Chen L; Chen Y; Li M; Gao C; Shang J; Xiang S; Li Y; Li J; Zhou C; Zhou X; Chen N; Liu Y; Liu J; Zhang Y; Chen X; Zhu D; Gao H; Tang L; Zhu M; Li L
Artif Organs; 2021 Jul; 45(7):762-769. PubMed ID: 33326621
[TBL] [Abstract][Full Text] [Related]
18. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
[TBL] [Abstract][Full Text] [Related]
19. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients.
Pedrosa M; Gomes J; Laranjeira P; Duarte C; Pedreiro S; Antunes B; Ribeiro T; Santos F; Martinho A; Fardilha M; Domingues MR; Abecasis M; P da Silva JA; Paiva A
J Tissue Eng Regen Med; 2020 Jan; 14(1):16-28. PubMed ID: 31502378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
